ESH ALL 2021 | The biology of T-ALL
Scott Armstrong, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, shares his highlights from the ESH ALL session on the biology of T-cell acute lymphoblastic leukemia (T-ALL). Different aspects of the disease were discussed, including resistance to therapies, relapse prevention, and mutations involved in the development of T-ALL. Research shows that DNA binding proteins collaborate with mutations in signaling molecules. Since both are required to drive leukemia, this has implications for targeted therapies in T-ALL. Additionally, Dr Armstrong talks on the use of T-cell receptor signaling as a new therapeutic approach. This interview took place during the 2021 European School of Hematology (ESH) 2nd Translational Research Conference on Acute Lymphoblastic Leukemia.
Disclosures
Sponsored Research: Syndax Pharmaceuticals, Novartis, Janssen.
Scientific Advisory Board: C4 Therapeutics, Imago Biosciences, Neomorph Inc.
